Evidence map›Paper›PMID 28386262›Full record

ArticleFrontiers in immunology2017

Preservation of Antigen-Specific Functions of αβ T Cells and B Cells Removed from Hematopoietic Stem Cell Transplants Suggests Their Use As an Alternative Cell Source for Advanced Manipulation and Adoptive Immunotherapy.

Giuseppina Li Pira, Stefano Di Cecca, Simone Biagini, Elia Girolami, Elisabetta Cicchetti, Valentina Bertaina, Concetta Quintarelli, Ignazio Caruana, Barbarella Lucarelli, Pietro Merli and 5 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 1 country.

Giuseppina Li PiraDepartment of Pediatric Hematology and Oncology, IRCCS Bambino Gesù Children's Hospital , Rome , Italy.
Stefano Di CeccaDepartment of Pediatric Hematology and Oncology, IRCCS Bambino Gesù Children's Hospital , Rome , Italy.
Simone BiaginiDepartment of Pediatric Hematology and Oncology, IRCCS Bambino Gesù Children's Hospital , Rome , Italy.
Elia GirolamiDepartment of Pediatric Hematology and Oncology, IRCCS Bambino Gesù Children's Hospital , Rome , Italy.
Elisabetta CicchettiDepartment of Pediatric Hematology and Oncology, IRCCS Bambino Gesù Children's Hospital , Rome , Italy.
Valentina BertainaDepartment of Pediatric Hematology and Oncology, IRCCS Bambino Gesù Children's Hospital , Rome , Italy.
Concetta QuintarelliDepartment of Pediatric Hematology and Oncology, IRCCS Bambino Gesù Children's Hospital, Rome, Italy; Department of "Medicina Clinica e Chirurgia", University of Naples Federico II, Naples, Italy.
Ignazio CaruanaDepartment of Pediatric Hematology and Oncology, IRCCS Bambino Gesù Children's Hospital , Rome , Italy.
Barbarella LucarelliDepartment of Pediatric Hematology and Oncology, IRCCS Bambino Gesù Children's Hospital , Rome , Italy.
Pietro MerliDepartment of Pediatric Hematology and Oncology, IRCCS Bambino Gesù Children's Hospital , Rome , Italy.
Daria PagliaraDepartment of Pediatric Hematology and Oncology, IRCCS Bambino Gesù Children's Hospital , Rome , Italy.
Letizia Pomponia BresciaDepartment of Pediatric Hematology and Oncology, IRCCS Bambino Gesù Children's Hospital , Rome , Italy.
Alice BertainaDepartment of Pediatric Hematology and Oncology, IRCCS Bambino Gesù Children's Hospital , Rome , Italy.
Mauro MontanariDepartment of Pediatric Hematology and Oncology, IRCCS Bambino Gesù Children's Hospital , Rome , Italy.
Franco LocatelliDepartment of Pediatric Hematology and Oncology, IRCCS Bambino Gesù Children's Hospital, Rome, Italy; Department of Pediatrics, University of Pavia, Pavia, Italy.
Istituti di Ricovero e Cura a Carattere Scientifico · ITBambino Gesù Children's Hospital · ITUniversity of Naples Federico II · ITUniversity of Pavia · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hematopoietic stem cell transplantation is standard therapy for numerous hematological diseases. The use of haploidentical donors, sharing half of the HLA alleles with the recipient, has facilitated the use of this procedure as patients can rely on availability of a haploidentical donor within their family. Since HLA disparity increases the risk of graft-versus-host disease, T-cell depletion has been used to remove alloreactive lymphocytes from the graft. Selective removal of αβ T cells, which encompass the alloreactive repertoire, combined with removal of B cells to prevent EBV-related lymphoproliferative disease, proved safe and effective in clinical studies. Depleted αβ T cells and B cells are generally discarded as by-products. Considering the possible use of donor T cells for donor lymphocyte infusions or for generation of pathogen-specific T cells as mediators of graft-versus-infection effect, we tested whether cells in the discarded fractions were functionally intact. Response to alloantigens and to viral antigens comparable to that of unmanipulated cells indicated a functional integrity of αβ T cells, in spite of the manipulation used for their depletion. Furthermore, B cells proved to be efficient antigen-presenting cells, indicating that antigen uptake, processing, and presentation were fully preserved. Therefore, we propose that separated αβ T lymphocytes could be employed for obtaining pathogen-specific T cells, applying available methods for positive selection, which eventually leads to indirect allodepletion. In addition, these functional T cells could undergo additional manipulation, such as direct allodepletion or genetic modification.

Indexed as

alloreactivityantigen-induced activationB-cell presentationgraft manipulationHLA-haploidentical transplantationαβ T cells

Identifiers

PMID28386262
PMCPMC5362590
OpenAlexW2601519575

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.